Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Melanoma 34Carcinoma, Non-Small-Cell Lung 22Carcinoma, Renal Cell 20Neoplasm Metastasis 13Carcinoma, Hepatocellular 10Brain Neoplasms 8Lung Neoplasms 7Skin Neoplasms 6Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Kidney Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Transitional Cell 5Uveal Melanoma 4Ovarian Neoplasms 4Myelodysplastic Syndromes 4Multiple Myeloma 4Glioblastoma 4Carcinoma, Basal Cell 4Carcinoma 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Sarcoma 3Recurrence 3Mesothelioma 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Histiocytoma, Malignant Fibrous 3

Interventions

Nivolumab 2trametinib 1selpercatinib 1lenvatinib 1fludarabine 1dabrafenib 1cemiplimab 1aldesleukin 1Radiotherapy, Intensity-Modulated 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × Ipilimumab × 90 days × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡